In this study, we systematically investigated the antitumor potential of fedratinib, a JAK2 inhibitor approved for myelofibrosis, against esophageal squamous cell carcinoma (ESCC) using integrated in vitro, in vivo, and patient-derived organoid (PDO) models. The gene discussed is JAK2; the disease is myelofibrosis.